Health insurance; terms; coverage of certain genetic testing and cancer imaging; terms of coverage; exclusions; effective date.
Summary
HB2270 would require most health benefit plans offered, issued, or renewed in Oklahoma on or after November 1, 2025, including the Oklahoma Employees Insurance Plan, to cover certain cancer-related genetic testing and evidence-based cancer imaging. The required testing is limited to clinical genetic testing for inherited gene mutations associated with increased cancer risk when the patient has a personal or family history of cancer, the test has clinical utility, and it is ordered or recommended by a health care provider consistent with recognized medical evidence and guidelines.
The bill also requires coverage for evidence-based cancer imaging for individuals at increased risk of cancer when the imaging has clinical utility and is ordered or recommended under NCCN or other nationally recognized clinical practice guidelines. Coverage under the bill could not be subject to annual deductibles, copayments, or coinsurance limits, although the bill includes an exception intended to preserve health savings account compatibility for qualified high-deductible health plans, except for preventive care items and services. The measure would be codified in Title 36 of the Oklahoma Statutes as Section 6060.5b.
Impact
HB2270 would add a new insurance mandate to Oklahoma law by requiring specified health plans to cover certain genetic testing and cancer imaging services without cost-sharing, subject to the bill’s medical-necessity and guideline-based limitations. It would affect insurers, the Oklahoma Employees Insurance Plan, health care providers ordering tests or imaging, and enrollees seeking cancer-risk evaluation or screening. The bill would also interact with federal tax rules governing health savings accounts and high-deductible health plans by limiting when the mandate applies in order to avoid HSA ineligibility.
Sentiment
Based on the available record, the bill appears to be framed as a health coverage expansion with a preventive-care and cancer-detection rationale, and there is no recorded committee transcript or vote history showing opposition or support. The absence of votes and discussion suggests the public record provided here does not capture broader debate, but the bill’s structure indicates an intent to align coverage with established clinical guidelines and reduce out-of-pocket costs for patients at elevated cancer risk.
Contention
The main potential points of contention are likely to be the insurance mandate itself, the requirement that plans cover services without deductibles or copays, and the cost implications for insurers and employers. Another possible issue is the bill’s reliance on NCCN and other nationally recognized guidelines, which may raise questions about how coverage decisions are made and whether the standards are sufficiently flexible. The HSA/high-deductible plan carveout may also draw attention from stakeholders concerned about preserving consumer choice and federal tax compatibility.
Medicaid; terms; Oklahoma Health Care Authority; coverage; Medicaid; criteria; medical necessity; discretion; Chief Operating Officer; Health Information Portability and Accountability Act; scientific research; consent; research; opting-out; minors; promulgation of rules and regulations; waiver application; effective date; emergency.